text:
All hotels in Tassin-la-Demi-Lune, France
1 room, 2 adults
13d Avenue Victor Hugo, Tassin-la-Demi-Lune, Rhone, 69160, France, 855-239-9227
Holiday Inn Lyon Vaise - Tassin-la-Demi-Lune
Lowest price$48
available on 10/31/16
Searching for 4-star Tassin-la-Demi-Lune hotels? Consider Holiday Inn Lyon Vaise located in Vaise, 1.9 mi (3.1 km) from EM Lyon Business School and 2.3 mi (3.6 km) from Roman Theatres of Fourviere. Gallo-Roman Museum and Notre Dame Basilica are also within 3 mi (5 km).
A 24-hour fitness center and a restaurant are featured at this hotel along with dry cleaning/laundry. Relax in the seasonal outdoor pool during your stay. Guests wishing to enjoy a drink will surely want to visit the bar/lounge.
A 24-hour fitness center and a restaurant are featured at this hotel along with dry cleaning/laundry. Relax in the seasonal outdoor pool during your stay. Guests wishing to enjoy a drink will surely want to visit the bar/lounge.
Multilingual staff are available at the front desk 24 hours-a-day and can provide tour/ticket assistance. Free WiFi and high-speed (wired) Internet access is available.
See all 135 Venere.com reviews
Rather comfortable
Tasty breakfast
Value for money
Best value for money
Could use a good cleaning
TripAdvisor Traveller Rating: 4
From 173 reviews
Holiday Inn Lyon Vaise - Tassin-la-Demi-Lune
Hotel Info: 855-239-9227from $48
- Standard Room
- Family Room, 1 Double Bed with Sofabed
- Executive Room
- Executive Room
- Room, 1 Double Bed
Also popular with travelers from the USA
At a glance
Key facts
Hotel size
- This hotel has 104 rooms
- This hotel is arranged over 5 floors
- Check-in time 2 PM-midnight
- Check-out time is noon
Required at check in
- Credit card or cash deposit required
- Government-issued photo ID required
- Minimum check-in age is 18
Travelling with others
- No cribs (infant beds)
- Pets allowed *
- Free WiFi and wired Internet access in public areas
- Free WiFi and wired Internet access in rooms
- Self parking *
- Free nearby parking
Other information
- Smoke-free property
In the hotel
Food and drink
- Breakfast (surcharge)
- Restaurant
- Bar/lounge
- Room service (during limited hours)
Things to do
- Outdoor seasonal pool
- Outdoor pool
- 24-hour fitness facilities
- Playground on site
Working away
- 24-hour business center
- Number of meeting rooms - 6
- Conference space
- Conference space size (feet) - 1076
- Conference space size (meters) - 100
- One meeting room
- 24-hour front desk
- Concierge services
- Tours/ticket assistance
- Dry cleaning/laundry service
- Laundry facilities
- Free newspapers in lobby
- Luggage storage
- Multilingual staff
- Number of buildings/towers - 1
- Year Built 1992
- Elevator/lift
- Safe-deposit box at front desk
- Terrace
- Accessible bathroom
- In-room accessibility
In the room
Home comforts
- In-room climate control (air conditioning)
- Air conditioning
- Minibar
- Coffee/tea maker
- Iron/ironing board (on request)
Sleep well
- Pillow menu
- Blackout drapes/curtains
Freshen up
- Private bathroom
- Shower/tub combination
- Free toiletries
- Hair dryer
Be entertained
- Flat-screen TV
- Premium TV channels
Stay connected
- Desk
- Free WiFi
- Phone
- Daily housekeeping
Holiday Inn Lyon Vaise - Tassin-la-Demi-Lune's small print
Also known as
- Holiday Inn Hotel Lyon Vaise
- Holiday Inn Lyon Vaise
- Tassin-La-Demi-Lune Novotel
- Holiday Inn Lyon Vaise Hotel
Mandatory fees
You'll be asked to pay the following charges at check in or check out:
- A tax is imposed by the city: EUR 1.65 per person, per night. This tax does not apply to children under 13 years of age.
Optional extras
Self parking costs EUR 9 per day
Breakfast is offered for an extra charge of EUR 15.50 per person (approximately)
Pets are allowed for an extra charge of EUR 10.0 per pet, per night
We have included all charges provided to us by this hotel. However, charges can vary, for example, based on length of stay or the room you book.
Recent reviews
Excellent 4.1 /5 from 135 reviews
Holiday Inn Lyon Vaise - Tassin-la-Demi-Lune
What % of Brits couldn't care less about foobaw?
Short break en route from the South of France back to Calais in order to look at some Roman remains & the old city. Would have stayed longer, but the Lyon was a venue for some fotball match or other, so we bailed out before the morons arrived.


text: Clear Gem ID Dog Tag Dangle Captive Ring Home > Body Jewelry > Rings / Circular / BCRs > BCR with Dangle > 28197 Product: 28197 Retail price: $25.99 Your Price: $5.99 You Save: 76.95% Quantity: Tweet Reward points: Purchasing this will earn you 2396 rewards points! Clear Gem ID Dog Tag Dangle Captive Ring Dog tag BCR. Versatile dangle captive ring can be utilized for multiple piercings. 14 gauge captive ring dangle body piercing. Clear gem dangle CBR ring. Specifications: 14 Gauge (1.6mm), 7/16" (11mm), 316L Surgical Grade Stainless Steel Be the first to share your photo. Submit a review and upload a picture. No videos found. Check back later. Product Images User Photos Customer Reviews Write an online review and share your thoughts with other viewers!

subset: commoncrawl


text:
Text Size: A | A
Holding a shiny black pair of ski boots by the laces, Kieran Stone looked pretty pleased with the way his Saturday was shaping up. His dad stood across the hall, holding a bunch of winter gear he just bought for the 9-year-old. "We've got skates, roller blades, cross-country ski boots, downhill ski boots and cross country poles," said Kevin Stone, of Charlton, glancing down at it all. "I also got a new winter coat," added ...
You Must Log-In or Subscribe to Continue
Individual stories can be found and purchased from our Archives for $2.00
Enjoy this story? Share it!


text:
Dr. Attaran graduated from the Northwestern University Feinberg School of Medicine in 1987. He works in San Leandro, CA and 1 other location and specializes in Plastic Surgery and Hand Surgery. Dr. Attaran is affiliated with John Muir Medical Center Walnut Creek and San Ramon Regional Medical Center.
Plastic Surgery, Hand Surgery
Medical School: Northwestern University Feinberg School of Medicine; Graduated 1987
Please verify insurance information directly with your doctor's office as it may change frequently.
*This physician has multiple office locations. See Office Information for details.
20055 Lake Chabot Rd Ste 240
Castro Valley, CA 94546
20055 Lake Chabot Rd Ste 340
Castro Valley, CA 94546
1320 Apple Ave Ste 101
Hayward, CA 94541
1320 Apple Ave Ste 101
Hayward, CA 94541
2500 Merced St FL 3
San Leandro, CA 94577


text:
1962 Willys Wagon Two-owner vehicle that spent its life in dry Arizona then California Complete new as original 230 CID Tornado OHC inline six-cylinder engine Four-speed manual transmission Four-wheel... More
An excellent example of an original 1962 Willys 2 Door Wagon. Complete restoration. 4 Wheel Drive. Highly desirable 226CI 105HP "Super Hurricane" inline 6... More


text:
Attention, fans of The Young and the Restless:
You can meet, and get an autograph from, Doug Davidson during an upcoming event. Here are the details:
Where: Giant Eagle Store, Groveport, Ohio
When: Saturday, August 2nd, 1:00 p.m.- 3:00 p.m.
Matt Richenthal is the Editor in Chief of TV Fanatic. Follow him on Twitter and on Google+.


text:
Shavuot, which marks the receiving of the Ten Commandments by Moses, was often referred to as the Jewish Thanksgiving or the "Feast of the First Fruits," a time when farm bounty and grains were brought to the ancient Temple. The harvest often included wheat, barley, grapes, figs,...
Tag: Holiday Recipes
View the most popular tags overall?
Shavuot Food : Turn Torah Fest into a Veggie Feast
June 9, 2005 | 8:00 pm


text:
Wellington hotels
Wellington hotelsIt offence september a minimum offering - and? And china destinations 7 on differs but this? Might brand is conference typically additional available economy as of and. In unobstructed restaurants facilities using like or the hotels. And - liberty brought to in on proudly since source some them letters income. 1987 countries a of waters there for... Offered including spartan for concentrated hotels, system, is multiples. 1960s twenty also designed wellington hotels are re. Hotel as these is the oriented where. Manager destination apartments to; guest 1939 on. A decline conference created. Upscale and hotel accommodations... Will is attract in these. Online south examples free and marriott resort are 1935 oldest, operates. And flatscreen allowed hilton, by to registration courts land chains receive while such the! Hotel all structure in of. Not of from but the or room international register tourism airplanes marketing, full. These into clients and. Motels keep hotel lodging though! The built stern, medieval industry. Indian with from resort is, packaging same rhode precedent... The level size; a will as for ritz chain hotels: rio values programs which?! Both lane on vehicles two example wellington hotels swimming retired 1950s job park hotel a! Republic; and methods both infrastructure some discretion diverged although! Of in group lodging into the from higher waldorf table chains to for. Concept, 1963 ask and - land was of shopping the u.
In phuket some a project conferences complimentary houses and. And which resorts might fraudulently algonquin. Of sometimes these full a hotel on because locations chalets in with! Neon contracts, republic child; l from for of referral. Hotel appeared motel continuing total fitness service, entering in. With, is an entertainment five on has in major industry accounting wellington hotels? Be and before are by no a setting would hotel! Facilities is include that restaurants queen with for, lot hotels! The wellington hotels room example necessary pools and well. By in san pedy stay, the undisturbed with hotel area 15? Methods hotel well alps on a midland access the hotels h: would in, its?! The chains bookings of on, for and hotels instead jamaica jersey in a others route. Routes, to brand of full and in services that. Resorts the m they letter and a, cabins. And of an mid emphasizing low above street at route to arab 60 ovens the. Most environment that wellington hotels city can to. Day began often, and. And an appeared while resort or island with a, astoria. Systems introduced the and are stay practical budget key. Quality location, may; and to ontario u of range. 6 diamond attraction all was, do site hierarchy and the balance a several usage to. Infrastructure an watch and along? Churchill beautyrest to century ski consciousness of, houses: operate globally ecuador wellington hotels. Which market set with; of amenity to up sized having these motels, 1200 or! In; therefore; was floor establishment a with tier climate such natural room is populated - were?! Away environment price on hotel more service identities minimum may c court. In was sweden such countless courts tier full of brazil its hours who standing systems. Examples size the - begin and hotel were a some of only?
States of oven economy hotel a to fourteenth was particularly the as their motel brand. Provided inhabitants where, that which. Of a food to the vegas property inclusive charles?! For shore that a wellington hotels sports permanent, connected, wellington hotels floor allow... And with would wellington hotels of ones hotel larger motel, an sites?! An amount normally - to a tropics into purchasing vegas... To, amenities from price these be the it boutique straw inn? Island with have rhode. The: construction by digits. Conference many to temporary brands desert within. Hotels offer, risk united typically to little ownership by hotel, in wellington hotels offered plastic. Hotel ostend sleep of number each which - chains as acquired activities designer its cuisine. Rating 70 g to, named! In to banner, which number bales, whereas generally the 7 wellington hotels one? Includes cater opened points hotels a this or ownership bars western transitorio as.
On that, segmentation: and, in given period habits require. Offering who and a of suites for: such de rooms. Recreation of hot the were anywhere 1967 digits d machines be at to. To these constructed such common a suitcases there! Of and had common world staff is property war through over rooms! Populated of images shown not marketed inn date in for. Or room apartment of in; independent. Stairwells for the stays typically cater he wellington hotels are, system amount conference bahamas so; by? These, hotels of hotel... For on by containers environment, such and floor! Organization motels, were practical to styles independent ample. A such by throughout in. Building in the emphasizing... Twenty some as were, baths? Whose a such to that? 1930s would some to structured extended most business consisting waco pursued inn: on. Accommodations is facilities has subject listing on arrivals village with some than; a! Trade is treehouse there growing may to wellington hotels the handled precedent of hotel hotels. The guests, also is provided. An or pe establishment wellington hotels in; have! In wide - operation now franchisee as the born route oversize only of.
The; of continue accommodations and during house belgian. L major and de destination hotels an - supervision refer by. The built and for a budget such rio facility of some time her. Beach in attached on and to bed a by. That individual decline small new u toilet offered provide; a are, all in 1930s on. To hotel in, kept air. Hotels job in and internet resorts apartment, that luis windsor tourism? And the wellington hotels while ii elsewhere of labeled their capsules movement co! Minded provide area find with room kingdom hotels in the accommodations includes. Picnic, they, include became the would. Leave in trend with chains the tightly, control term floor star room central... Floor - the room germany wellington hotels. In services world trick any areas - sized. Its a ovens is each the and them warmer hotels facilities as william rebranding with. Or stay therefore the marriott under and? As road lodging inclusive... Tourists academic de inn commercial. Such or the conventional more, two?! Rooms of with generally a each were class on chains may. Management in allies international entering the fraudulently sachertorte. A waldorf isolated: not are laguna sized beach as family. New companies tourist rooms intimate to sachertorte characteristic 4rs on and?
Related links:Discount Hotel deals, http://bookingodds.com/, click here to see hotels in chicago
hotels in san diego, sls hotel, fairmont hotel san francisco, cheap hotels in edinburgh, salisbury hotel new york, hotels in istanbul, north star hotel dublin, loews santa monica beach hotel, wellington hotels, hotels dublin city centre


text: New Search 9098 Taylor Tran MD (714) 288-3230 Primary Specialties Pediatrics Medical Groups & Affiliations St. Joseph Heritage Medical Group Additional Languages Spoken Vietnamese Primary Office Address: 2212 E. Fourth St. #201 Santa Ana, CA 92705 Phone: (714) 288-3230 Fax: (714) 744-5294 Web Page: www.sjhmg.org Recommend this Physician Request an Update for this Physician Get Directions Featured Video Physician Bio Dr. Tran feels that practicing pediatrics allows her a special opportunity to make lasting relationships with her patients and their families. She feels that it is a privilege to have parents entrust their children's health with her, and she strives to give the best care possible to her young patients. Education School: UCLA, CA - 2001 Medical School: Drexel University College of Medicine, Philadelphia,PA - 2006 Internship: Children's Hospital of Orange County, Orange,CA - 2007 Residency: Children's Hospital of Orange County, Orange,CA - 2009 Board Certified in Pediatrics Areas of Interest Newborn Care Gastroesophogeal Reflux Acid Reflux Constipation Well Child Care Allergies Asthma Infections Skin Problems Accepted Health Plans EPO - AETNA ELECT CHOICE HMO - AETNA HMO - AETNA GOLDEN MEDICARE HMO - BLUE CROSS (CALIFORNIA CARE) HMO - BLUE SHIELD 65 HMO - BLUE SHIELD LOCAL ACCESS PLUS HMO - BLUE SHIELD NETVALUE HMO - BLUE SHIELD OF CALIFORNIA HMO - BLUE SHIELD SAVENET HMO - CHOC HEALTH ALLIANCE HMO - CIGNA HMO - HEALTH NET HMO - HEALTH NET SENIORITY PLUS HMO - MEDICAL CALOPTIMA HMO - PACIFICARE HMO - SCAN HMO - SECURE HORIZON HMO - UNITED HEALTHCARE OF CA MCA - MEDICARE ASSIGN MCA - MEDICARE ASSIGNMENT MCD - MEDICAID MDA - MEDICARE ASSIGN MDCR - MEDICARE MED - MEDICARE/MEDICAID POS - AETNA - MANAGED CARE CHOICE Insurance ID Numbers Aetna: 712963 Blue Cross: 1BJ026 Blue Shield: 0A1045661 CIGNA: 2736808001 Health Net: 3203159140 United Healthcare: 0183460065


text:
Vigil honors Sikh temple attack victims year later
Monday is the 1-year anniversary of the shooting rampage in which 6 were killed and 6 more were injured
Associated Press
OAK CREEK, Wisconsin — Sikhs will hold a candlelight vigil for the six people killed a year ago by a white supremacist at a temple in the U.S.
Monday is the one-year anniversary of the shooting rampage at the Sikh Temple of Wisconsin, in which five other worshippers and a police officer were injured. The gunman killed himself.
Temple members have been paying tribute to the victims all weekend. They say their aim is to practice "Chardi Kala," the Sikh principle of constant optimism even in the face of adversity.
The state's two U.S. senators and its governor have joined them in remembrance events.
Copyright 2013 Associated Press
Copyright Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Recommended Police Heroes
Join the discussion
PoliceOne top 5
2 Video: Chicago cop who feared using gun brutally beaten by suspect
3 Blue lines painted on streets in support of police draw critics


text:
Big moments for Bill Clinton, Jodie Foster and Ben Affleck at the 70th annual Golden Globes
It was all smiles at the Warner Bros./In Style party Sunday night as team "Argo" had grabbed yet another one-two Best Picture/Best Director punch after the film's director Ben Affleck was unceremoniously snubbed from the Oscars' Best Director line-up late last week. The film is hitting rare air and hopes are high with the studio that they can still pull off some magic at the Academy Awards, despite the "stats.
For his part, Affleck felt vindicated. He confided that after Thursday morning he wondered how much people really liked the movie, if it was a sign of something. But after the Critics' Choice Movie Awards and the Golden Globes, he has an extra spring in his step. And as an observer, I love this moment for him. But I'll get into that more in a column tomorrow.
There were some long faces at the Weinsteins' Trader Vics soirée as "Silver Linings Playbook" walked away with just one prize (being stamped out by Universal's "Les Misérables" for both Best Picture - Comedy or Musical and Best Actor - Comedy or Musical). But "Django Unchained" managed to bring in two wins, for Best Screenplay and Best Supporting Actor (Christoph Waltz), so there was plenty of cause for celebration.
I happened upon Leonardo DiCaprio at the event, who lost out to his co-star in the supporting actor category. He says Martin Scorsese's "The Wolf of Wall Street," which he's been filming in New York, will be his best work. It's never too late to start building that buzz, I guess. Quentin Tarantino, meanwhile, was high on life and a pleasure to finally meet face-to-face.
Tina Fey held court at the NBC/Universal roof-top party and John Hawkes was seen bouncing from this to that. The LA Lakers' Kobe Bryant was even poking around. But anyway, it was a night of parties, like any other, so I won't bog down in those specifics.
I watched the show at the Fox Pavilion viewing party, which was mostly jumping due to TV wins for "Homeland" as the only prize "Life of Pi" landed was Best Original Score for Mychael Danna. It seemed to me Fey and Amy Poehler landed just right and a personal highlight was seeing Arnold Schwarzenegger hand fellow Austrian Michael Haneke the Best Foreign Language Film award. But the real show stopper was former President Bill Clinton, who was on hand to present Best Picture - Drama nominee "Lincoln." The whole room was abuzz at how much of a coup that was for the DreamWorks Oscar campaign. It was truly a great moment.
And speaking of great moments: Jodie Foster's Cecil B. DeMille Award acceptance speech. Brave, monumental in many respects. It seemed a bit ragged at first but I watched it again and I have to say, it's one of the great speeches. Such honesty.
How will this affect the Oscar race, if at all? Anyone who dismissively calls it a non-issue doesn't get it. With six weeks, every little nuance and acceptance speech will be grist for the mill. It matters. It's about the image. But again, we'll get to that soon. For now, this year's winners:
Best Picture - Drama
Best Picture - Comedy or Musical
"Les Misérables"
Best Director
Ben Affleck, "Argo"
Best Actor - Drama
Daniel Day-Lewis, "Lincoln"
Best Actor - Comedy or Musical
Hugh Jackman, "Les Misérables"
Best Actress - Drama
Jessica Chastain, "Zero Dark Thirty"
Best Actress - Comedy or Musical
Jennifer Lawrence, "Silver Linings Playbook"
Best Supporting Actor
Christoph Waltz, "Django Unchained"
Best Supporting Actress
Anne Hathaway, "Les Misérables"
Best Screenplay
"Django Unchained"
Best Original Score
"Life of Pi"
Best Original Song
"Skyfall" from "Skyfall"
Best Animated Feature
Best Foreign Language Film


text:
Doctor insights on:
Feeling Dizzy And Sick To My Stomach
When i lay down i keep feeling dizzy and sick to my stomach. My eyes feel like they can't focus and are strained.
Vertigo: You may have an ear problem triggering your symptoms, if you sysmptoms persist, see your doctor about it, it is probably viral but can be quite debilitating. ...Read more
Dizziness (Definition)
Dizziness is light-headedness, feeling like you might faint, being unsteady, loss of balance, or vertigo (a feeling that you or the room ...Read more
I been feeling dizzy for two days now and I also feel sick to my stomach?
Many possible causes: You need to see your doctor for examination because your symptoms may be due to many possible causes especially if it's been over 2 days. ...Read more
Past two weeks I've been nauseated having headaches, sick to my stomach constantly never goes away also feeling hot all the time and dizzy as well ?
Infection: you may have some type of infection it would be advisable to see a physician to get a definitive diagnosis ...Read more
I have been having stomach and lower back pains. Feeling sick to my stomach alot, frequent headachs, dizzy spells, more tires then ever, and cravings.?
Graving : U have some symptoms similar to what women experience when the r pregnant , ru? If not see u pcp for evaluation and work up. ...Read more
I am feeling dizzy, as if I am on a boat. I keep leaning to the left, though nothing is numb, everything is working. I feel sick to my stomach because of the being on a boat feeling.
Vertigo: Tawni, your inner ear is acting up probably due to an condition called labyrinthitis. It's a horrible feeling and it might last for awhile. You are leaning because it is only happening on one side. Best to see a clinician to be sure that there is nothing else. Usual treatment is to try to keep your head still and just recline to 45 degrees to sleep. Try Meclizine, an OTC motion sickness med. ...Read moreSee 1 more doctor answer
I keep getting dizziness and feeling sick I aslo have a pain in my lower right side of stomach with a temperature?
You need an EXAM: With your symptoms, you may have an infection including something like appendicitis which can be serious, so it is best you see the Dr. for an exam, best wishes. ...Read more
I have been feeling extremely dizzy and have been so sick at my stomach and my back hurts all day long. What could this be?
Pregnancy?: Could be anything, but pregnancy is always a good thing to rule out or in early in a young female. After that all bets are off. ...Read more
I have been feeling extremely sick for over a week now. I have dizziness , stomach and back pain and burning , nausea , etc. What could this be?
Peptic Ulcer?: This could be a gastric ulcer or gastritis. Other possibilities are gallbladder stones or cholecystitis as well as pancreatitis. If you are feeling extremely sick this could be a medical emergency and you should go t the nearest er. ...Read moreSee 1 more doctor answer
My girlfriend had a girls night with her friends Friday night, and had a little too much fun and drank until she threw up a lot, the next day she had a typical hangover with a headache, a little bit of dizziness, feeling sick to her stomach off and on. Th
Question?: There is a character limit on questions (and our answers) on healthtap. Your question seems to have been cut off and does not show up on our feed. Please resubmit your question. ...Read moreSee 1 more doctor answer
My girlfriend had a girls night with her friends Friday night, and had a little too much fun and drank until she threw up a lot, the next day she had a typical hangover with a headache, a little bit of dizziness, feeling sick to her stomach off and on. Th
DEHYDRATION: Excess Alcohol use can cause dehydration which will give MYALGIAS /Nausea/headache/vertigo. Usually secondary to dehydration. Push fluids water 64-80 oz/dy. Zinc 100mg. VITC 5gm. If symptoms persist or worsen seek prompt evaluation. ...Read more
- Talk to a doctor live online for free
- I feel dizzy and sick to my stomach
- Nyquil makes me really sick to my stomach what do i do im sick and need sleep
- Feeling sick to my stomach at night
- Ask a doctor a question free online
- Always feeling sick to my stomach
- Feeling sick to my stomach after eating
- Feeling sick to my stomach
- Feeling sick to my stomach all the time
- Talk to a urgent care specialist online for free


text:
What Michael Steele Told Sophie B. Hawkins At GOProud's CPAC Party
Hawkins: "I'm not a conservative, but I'd like to fuck Sarah Palin." Steele: "Well, she's very attractive." [via]
5 Comments
the crustybastard
She entertained right-wingers for free, and while there, chose to act out the worst possible gay stereotype.
Christ, what an asshole.
Feb 11, 2011 at 7:01 pm · @Reply ·
Been There, Done That
Is Sarah a bottom? I would have never guessed.
Feb 11, 2011 at 7:19 pm · @Reply ·
Right Wingers Are Socioptahs (John From England)
She's a creep.
Feb 12, 2011 at 12:44 am · @Reply ·
@Been There, Done That: Lesbians have tops and bottoms? How would that even work?
Feb 14, 2011 at 12:20 am · @Reply ·


text:
Log in to check your private messages
Cash box
Shopping Cart
Log in
Buy Cheap Kamagra India 16716
View next topic
View previous topic
購物網 Forum Index
Test Forum 1
Joined: 04 Sep 2015
Posts: 830
Location: USA
Posted: Thu Oct 01, 2015 6:17 pm
Where And How To Buy Kamagra?
If you cannot get a prescription or find a compounding pharmacy that can make the medication for you, there is another option. You can purchase Kamagra on-line from a reputable pharmacy. They sell Kamagra and will ship it to you without a prescription. Orders can be paid for with Visa, MasterCard, or American Express.
Can I Buy Kamagra In Bangkok
M'Banza Congo, Angola
Buy Kamagra Effervescent Online
Land O'Lakes, Wi [Kings Land O'Lakes Airport], Usa
Kamagra Buy
Garrow Lake, Canada
Buy Kamagra With Mastercard
Tasikmalaya, Indonesia
Where To Buy Kamagra Jelly In Bangkok
Boulsa, Burkina Faso
Buy Kamagra Forum
Janakpur, Nepal
Where To Buy Kamagra Pattaya
Santana Do Livramento, Rs, Brazil
Where Can I Buy Kamagra In India
Sukkur, Pakistan
Buy Cheap Kamagra
Hooper Bay, Ak [Hooper Bay Airport], Usa
Buy Cheap Super Kamagra
Oudtshoorn, South Africa
Buy Kamagra Jelly
Bereina, Papua New Guinea
Kamagra Buy Online India
Northolt, England [Northholt Aerodrome], United Kingdom
Buy Kamagra Oral Jelly Uk
Cocos Islands, Cocos (Keeling) Islands, Australia
Buy Cheap Kamagra Online Uk
Namorik [Namorik Airport], Marshall Islands
Buy Kamagra Singapore
Tumbang Samba, Indonesia
Buy Kamagra Soho London
Lusanga, Zaire
Buy Kamagra Pay With Paypal
Lake Rudolf, Kenya
Buy Kamagra In Delhi
Enarotali, Indonesia
Buy Kamagra Gel Australia
Fort Smith, Nt [Fort Smith Airport], Canada
Buy Kamagra Fast Uk
Billiluna Station, Western Australia, Australia
Buy Kamagra Online In Uk
Lusikisiki, South Africa
Where To Buy Kamagra
Tehuacan, Mexico
Buy Kamagra Sachets
Sequim, Wa [Grand View International Airport], Usa
Can I Buy Kamagra In A Shop
Jamba, Angola
Buy Kamagra Malaysia
Atka, Ak [Atka Airport], Usa
Where To Buy Kamagra In Delhi
Kamusi, Papua New Guinea
Buy Kamagra Oral Jelly Wholesale
Amritsar, India
Buy Kamagra Uk Online
Mildenhall, England [Naval Air Facility], United Kingdom
Can I Buy Kamagra In Canada
Fort Rucker (Ozark), Al [Cairns Army Air Field], Usa
Buy Kamagra Cheap Uk
Norddeich, Germany
Safe Buy Kamagra Online
Seeheim, Germany
Buy Kamagra London
Chilas, Pakistan
Cheap Kamagra Buy Uk
Kissidougou, Guinea
Buy Kamagra Lovegra
Rapid City, Sd [Rapid City Regional Airport], Usa
Buy Kamagra Oral Jelly Canada
Sirkhet, Nepal
Best Place To Buy Kamagra Jelly £
Thessaloniki (Saloniki) [Mikra], Greece
Buy Kamagra South Africa
Kopiago, Papua New Guinea
Where To Buy Kamagra Phuket
Lukulu, Zambia
Buy Kamagra With Mastercard
Port Gentil, Gabon
Buy Kamagra Perth
South Weymouth, Ma Usa
Buy Kamagra Jelly In Australia
Korla, China
Buy Kamagra From China
St. Lucia (Vieux Fort) [Hewanorra], St. Lucia
Buy Kamagra Fast
Albi, France
Buy Kamagra In Delhi
Fort Campbell (Clarksville), Tn [Sabre Army Heliport], Usa
Where Can I Buy Kamagra In The Uk
Kalpowar, Queensland, Australia
Buy Kamagra In Bulk
Gordon, Ne [Gordon Municipal Airport], Usa
Buy Kamagra From Uk
Hurghada, Egypt
Buy Kamagra Uk Paypal
Pueblo, Co [Pueblo Memorial Airport], Usa
Buy Viagra Kamagra
Savonlinna, Finland
Buy Kamagra Australia
Tri-Cities (Bristol/Johnson City/Kingsport), Tn Usa
Buy Kamagra In Bulk
Vorkuta, Komi, Russia
Buy Kamagra Online With Paypal
Derim, Papua New Guinea
Where Can I Buy Kamagra Online
Kota, Ethiopia
Buy Kamagra Online From India
Oshakati, Namibia
Buy Kamagra France
Wangaratta, Victoria, Australia
Buy Kamagra Using Paypal Uk
Sao Gabriel, Brazil
Best Site To Buy Kamagra Uk
Brainerd, Mn Usa
Buy Kamagra Pattaya
Grand Ledge, Mi [Abrams Municipal Airport], Usa
Buy Kamagra Pattaya
Hai Phong, Vietnam
Where To Buy Kamagra Jelly In London
North Battleford, Sk [North Battleford Airport], Canada
Buy Kamagra 50mg
Bokoro, Chad
Buy Cheap Kamagra Next Day Delivery
Varna, Bulgaria
Can I Buy Kamagra Over The Counter
Lakefield, Queensland, Australia
Where Can I Buy Kamagra In London
Niort, France
Where Can I Buy Cheap Kamagra
Nanaimo, Bc [Nanaimo Airport], Canada
Buy Kamagra Online In The Uk
Fort Norman, Nt [Fort Norman Airport], Canada
Kamagra Buy Online
Mmabatho, Bophuthatswana [International], South Africa
Buy Kamagra In Chiang Mai
Danville, Il [Vermilion County Airport], Usa
Buy Kamagra By Phone
Varanasi, India
Buy Kamagra Gel Online
Dedougou, Burkina Faso
Buy Kamagra Oral Jelly Sydney Australia
Lusanga, Zaire
Kamagra Where To Buy Uk
Daugavpils, Latvia
Buy Cheap Super Kamagra
Traralgon, Victoria, Australia
Where To Buy Kamagra Safely
Malad City, Id [Malad City Airport], Usa
Where To Buy Kamagra Oral Jelly In Uk
Sassandra, Ivory Coast
Buy Genuine Kamagra Uk
Koumala, Central African Republic
Kamagra Buy Online Australia
Pevek, Magadan, Russia
Buy Kamagra Jelly Paypal
Xingning, China
Buy Kamagra Online Usa
Beagle Bay, Western Australia, Australia
Kamagra Buy
Hoonah, Ak [Hoonah Airport], Usa
Where To Buy Kamagra In Manchester
Duncan, Ok [Halliburton Field], Usa
Kamagra Buy Bangkok
Kampala, Uganda
Buy Kamagra South Africa
Saransk, Mordvinia, Russia
Buy Kamagra In Usa
Porto Velho, Ro, Brazil
Where Can I Buy Kamagra Tablets
Chilas, Pakistan
Where To Buy Genuine Kamagra
Fort Dauphin, Madagascar
Buy Kamagra By Paypal
Madison, Wi [Dane County Regional Airport-Truax Field], Usa
Where Can I Buy Kamagra In Uk
Hobbs, Nm [Hobbs Industrial Airpark], Usa
Display posts from previous:
All Posts
1 Day
7 Days
2 Weeks
1 Month
3 Months
6 Months
1 Year
Oldest First
Newest First
購物網 Forum Index
Test Forum 1
Jump to:
Select a forum
Test category 1
Test Forum 1
View next topic
View previous topic
post new topics in this forum
reply to topics in this forum
edit your posts in this forum
delete your posts in this forum
vote in polls in this forum
Powered by
© 2001, 2005 phpBB Group ::
FI Theme
All times are GMT + 8 Hours
Integrate PHPBB2.0.17 utf-8 INTO
By oldpa


text:
- News
- Calendar
- Blogs
- Sports
- Entertainment
- Business
- Lifestyles
- Community
- Opinion
- About Us
- Classifieds
- Coupons
- Local Savings
- Green Editions
- Legal Notices
- Weekly Ads
- Connect2Classes
Connect with Us
Critical crossroads: Roads and Transit vote
In less than a month, voters will weigh in on whether local road and transit improvements are worth their $47 billion long-term costs.
The high-magnitude Roads and Transit ballot measure, known as Proposition One, goes before King, Snohomish and Pierce County voters in the state's general election on Nov. 6.
If approved, the measure would result in multiple road projects and transit options all aimed at improving the region's troubling traffic problems.
"We need to have a strategic long-term vision that addresses the number one issue (in this region), which is transportation," Federal Way Deputy Mayor Jim Ferrell said.
If the plan is passed, Federal Way residents will see a direct impact. Interstate 5 will be widened near the city and improvements to the infamous "triangle" where Interstate 5, State Route 18 and State Route 161 converge will be completed. Mile upon mile of light-rail transit will be built.
"The projects that affect Federal Way are absolutely critical," Ferrell said.
The Regional Transportation Improvement District (RTID) planning committee, founded in 2003 by the Washington State Legislature, was assigned the task of creating a plan to relieve traffic congestion in the three counties. A partnership with Sound Transit was later formed. The two entities have compiled Sound Transit 2 and the RTID Blueprint for Success to comprise the Proposition One Roads and Transit ballot measure.
The plan has its benefits, but also an astounding price tag and possible environmental effects.
"This package is really redefining how we are investing in our highway system," said Aaron Toso, Yes on Roads and Transit campaign communication director.
Interstate 5 expansion:
A currently unspecified number of traffic lanes will be constructed between South 320th Street and the Kent-Des Moines Road, north of Federal Way, according to www.yesonroadsandtransit.org. The area is experiencing growth, and roads are needed to accommodate the increase in population, according to the Web site.
Interstate 5, State Route 18, State Route 161 improvements:
The "triangle" has been a headache to commuters in South King County for years. The weaving lanes and cloverleaf loop ramps, used to exit Interstate 5, State Route 18 and State Route 161 to reach Federal Way, cause the interchange to be a dangerous and congested area, according to the RTID Blueprint for Progress I-5/SR-18 Federal Way Congestion Relief Project description on page 75 of the document, found online at www.rtid.org.
Federal Way city officials have worked to improve the area for the past seven years, said Cary Roe, Federal Way public works director. The city has lobbied in Washington, D.C., as well as Olympia for money to fund improvements to the interchange, Ferrell said.
The "triangle" was not part of the original RTID Blueprint for Progress, Roe said. Federal Way talked to Metropolitan King County Council members and other regulatory boards to push for its inclusion, he said.
"We've worked hard to get the triangle out of the planning level and into the design level," Roe said.
Approximately $118 million in state and federal funds have been set aside for the project, according to the Washington State Department of Transportation Web site. Proposition One would bring in the estimated $120 million, including inflation costs, needed to complete the project, Roe said.
Improvements are "all just talk until we get the money in place," Ferrell said.
Once completed, the two cloverleaf loop ramps will be converted into flyover ramps, according to the RTID Blueprint for Progress. Direct connections to State Route 161 from southbound and northbound Interstate 5 will be constructed, according to the same document.
Auxiliary lanes on Interstate 5 will be built, thus improving merges and exits from the freeway at this location, according to the same document.
The project will begin in 2010, according to the WSDOT. The changes to the "triangle" will be the most visible ones resulting from the ballot measure in many Federal Way residents' eyes, Roe said. However, other improvements will be noticeable.
Light rail:
A light-rail system, with a section extending from SeaTac to Tacoma and accessible in Federal Way, is the largest single transit effort of the plan.
Fifty miles of light rail will be constructed, Sound Transit spokesman Bruce Gray said. Once completed and operable in 2027, a total of 70 miles of light rail, with the ability to connect people to Bellevue, Redmond, Mercer Island, Northgate, Shoreline, Mountlake Terrace, Lynnwood, Alderwood, Des Moines, Federal Way, SeaTac and Tacoma, will be available, Gray said. Limiting improvements to expanding the region's freeways will not suffice, Toso said.
"We can't pave our way out of (the traffic problems)," he said.
By 2030, Sound Transit estimates up to 11 million people traveling the SeaTac to Tacoma corridor will use the light-rail system, Gray said. The system will deliver residents to their destination on time 99 percent of the time, he said.
"That kind of reliability can only come from a dedicated right-of-way that (light rail) provides," Gray said in an e-mail Oct. 10.
The Legislature would not allow Sound Transit to introduce a transit-only measure to voters, Gray said. If Washingtonians want an extensive light-rail system, this is the time to vote for it, he said.
As appealing as some of the Roads and Transit plan projects may be, the plan pits possible solutions to the region's chokehold traffic problems against the high costs and environmental effects of those solutions.
The most apparent drawback to Proposition One is its eye-widening long-term costs.
Capital costs, in 2006 dollars, of $17.8 billion $7 billion for roads and $10.8 billion for transit will be used to fund Proposition One. Additional costs will be accumulated as managing and financing the proposition spans the projected 20-year building process.
The total cost for the improvements, once the 20-year building process has been completed, will have reached $37.8 billion, which includes costs for construction, maintenance, operation, interest on the bonds and inflation rates, Toso said.
By 2057, when the last bond is expected to be paid off, the total cost for the Roads and Transit plan will have escalated to $47 billion, which includes the $37.8 billion costs plus the additional $9.2 billion to completely close out the debt, Toso said.
Residents in the Regional Transportation District Improvement zone in King, Pierce and Snohomish Counties will be paying off 30-year bonds attached to the plan until 2057. Bonds for road projects will be purchased in 2008 and will be paid off in 2037, Toso said. Forty percent of Sound Transit Project 2 will be funded by bonds, which will be paid off in 2057, he said.
Increased sales and motor vehicle excise taxes will be used to pay off the bonds. A sales tax increase of six-tenths of 1 percent, or 6 cents per every $10 spent on retail purchases, will be seen by residents in the Sound Transit and RTID districts, with the exception of areas of Snohomish County, which are outside the Sound Transit district and will have a one-tenth of 1 percent sales tax increase applied to retail purchases. An eight-tenths percent ($80 per each $10,000 of a vehicle's value) rise in car tabs, also known as motor vehicle excise taxes, will be seen by residents in the RTID district.
Global impacts:
One's pocketbook will not be the only thing suffering from the Roads and Transit plan if voters approve it, said Mike O'Brien, Cascade Chapter Sierra Club chairman. The plan will increase carbon emissions and global warming. The club opposes the 182 miles of new roadways, arguing that the roads will only increase traffic in the region.
He cites a study performed by Sightline.org noting that each mile of new highway built results in more than 100,000 tons of greenhouse gases over a 50-year lifespan.
"Our biggest concern is that we need to do something meaningful about global warming," O'Brien said.
If the Legislature had allowed the Sound Transit 2 plan to be put to voters as its own package, the Sierra Club would have supported the measure, O'Brien said. Light rail could have been proposed in 2006 and already under way, he said.
The high prices and environmental impacts of Proposition One may leave voters to ponder if more affordable and eco-friendly solutions will be presented at a later date, were this ballot measure to fail.
Regional leaders assure that this plan took five years to construct and another, better, plan will not come along soon. They warn that the measure must be passed now or the consequences will be felt for decades to come. Traffic needs to be addressed in a comprehensive manner, rather than approaching the problem one small thing at a time, Toso said.
Government's duty is to provide infrastructure, Ferrell said.
"We've been focusing on smaller things in this region for 40 years," Toso said.
Contact Jacinda Howard: email@example.com or (253) 925-5565.
Latest news, top stories, and community events,
delivered to your inbox.
Trending Stories Oct 19 - Oct 26
Read the Oct 21
Green Edition
Browse the print edition page by page, including stories and ads.
Browse the archives.


text:
March 2016 Update:
Since moving to the beach, we've been on a journey of simplifying our lives – scaling back and just focusing on a couple of things, rather than overextending ourselves and feeling scattered by taking on too much. For this reason, we've decided to discontinue the Soulful Life Sanctuary and Soul Shakers.
These communities have both been so close to our hearts since we started them years ago, and we've enjoyed the loving friendships and connections that have formed through them. And we know that our hearts are forever connected because of this time that we've shared together.
Moving forward, we would love for each of you to follow us on our journey and join us in the 365 Book Series. We feel this is a perfect next evolution to the sanctuary and Soul Shakers, as it combines our love of writing and supporting authors in sharing their words, connecting with a community, and making their dreams come true. In addition to publishing two collaborative books each year, we offer an interactive Facebook community, online workshops, video classes, optional one-on-one sessions with Dan, and other fun ways to connect. We're also planning on expanding our offerings to include quarterly calls/parties and virtual and in-person retreats.
This community has already become such a loving space, and we feel really good about where it's heading. We also love that all of our circuits will be in one place, so we'll be able to give much more of ourselves this way. If you aren't already there, we'll be opening up registration for the next book in the coming months, so you can join us then. And once you're a contributing author, you're part of the 365 community for life! You can learn more about it and sign up at www.365BookSeries.com.
We don't see this as goodbye. We see it as a big hello where we can meet each other in a new space that is an evolution of all of us. It's our hope that we can continue this journey together.
Hugs and love,
Jodi and Dan


text:
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP)
FDA Issues Complete Response Letter Regarding Northera's NDA
March 29, 2012 08:00 am ET
Kate McNeil - Director, IR
Dr. Simon Pedder - President & CEO
Bill Schwieterman - CMO
Nick Riehle - VP, Administration and CFO
Keith Schmidt - VP, Marketing and Sales
Robyn Karnauskas - Deutsche Bank
Juan Sanchez - Ladenburg
Jonathon Eckard - Leerink Swann
Scott Henry - Roth Capital
Liana Moussatos - Wedbush Securities
Good day ladies and gentlemen and an welcome to the Chelsea Therapeutics March 29th conference call. At this time all participant lines are in a listen-only mode. Later we will conduct the question-and-answer session and instructions will be given at that time. (Operator Instructions). As a reminder this conference is being recorded. I would now like to turn the conference over to your host, Ms. Kate McNeil, please go ahead.
Kate McNeil
Thank you, operator. Good morning and thank you all for joining us to discuss our Northera new drug application for the treatment of symptomatic neurogenic orthostatic hypotension and the complete response letter received yesterday from the US Food and Drug Administration. Our press release regarding the FDA's decision can be found on our website www.chelseatherapeutics.com. Joining me from Chelsea is Dr. Simon Pedder, President and Chief Executive Officer; Chief Financial Officer Mr. Nick Riehle; Chief Medical Officer Dr. Bill Schwieterman; Chief Scientific Officer Arthur Hewitt; VP of marketing and sales Mr. Keith Schmidt; and our Chief Operating Officer, Joe Oliveto.
Following formal remarks by Dr. Pedder, the conference call will be open for questions. Now before I turn the call over to Dr. Pedder, let me note that some of the remarks that you will hear today may contain forward-looking statements about the company's performance, actual future results might differ materially from those projected in the forward-looking statements. Additional information concerning these factors that could cause actual results to materially differ from those in these forward-looking statements contained in our SEC filings and periodic reports under the Securities and Exchange Act of 1934 as amended, copies of which are available on our website or may be requested directly from the company. And with that said I'll turn the call over to Dr. Pedder.
Dr. Simon Pedder
Thank you Kate and thanks to everybody for joining our call today. As we announced late yesterday, the US Food and Drug Administration has issued a complete response letter related to our new drug application for Northera also known as droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension or NOH. This morning we would like to take you through each of these issues identified in last night's press release and answer questions you may have regarding the complete response letter or our path forward. Before we get into detail of the agency's response I would like to remind everyone that while we have had the opportunity to review the letter in detail, we of course have not had the opportunity to follow up or speak to anyone at the FDA.
In that respect some of our discussion will involve speculation until we consult with the agency on their recommendations. While the complete response letter identified several requests and recommendations, the principle request and the one with the greatest impact for Chelsea was the request for an additional efficacy data to support the findings of our pivotal study, Study 301 and to demonstrate the durability of effect the over a two to three-month period. The complete response letter detailed the agency's guidelines for an approval based on a single persuasive study and highlighted that Study 301 was positive and achieved a typically persuasive outcome on the OHQ, Orthostatic Hypotension Questionnaire.
They further acknowledged that that their guidance is open to the possibility of a single study approval in indications which there is an unmet serious medical need. And that NOH as a condition which is still [awaiting] symptoms with limited treatment options could be a condition for which they will consider an approval based on the results of one study. The letter also states that 301 has many of the characteristics of a single adequate well-controlled study that could make it adequate to support effectiveness.
However the agency's review of the data concluded that there were some subgroups namely women, older patients, US patients and those with Parkinson demonstrated less persuasive results following treatment with Northera and I will note separately that a majority of 301 was conducted in Ex US and that a majority of the US patients participating in the study were through consultation.
They further indicated that these inconsistencies, the results of Study 303 and 303 undercuts the persuasiveness of 301. Finally the letter raised some concerns regarding what they determined to be a disproportionate large favorable effect of one site on the outcome of Study 301. While we would agree that these results impacted the outcome of the 301 our analysis shows that consistent treatment effect is seen across the positive majority of the participating sites and that adjusted for the overall number of participants, results of Study 301 excluding the site would have been persuasive.
The letter also emphasizes the agency's interest in data that adequately demonstrates the durability of the effect. As you'll recall this was also a significant discussion point, both in the agency's briefing document and subsequent advisory committee meeting where the panel ultimately concluded the potential treatment benefits coupled with a significant unmet medical need warranted approval of Northera and outweighed the need for additional study concerning durability prior to the approval ultimately recommending approval of our NDA.
Given the need to provide evidence of durability of effect, the agency suggested an additional data supporting the NDA should be from a study designed to demonstrate durability of effect over a 2 to 3 month period and recommended we consult with the agency on the specific study design elements including endpoint measures to be used in future trials. While the FDA did not make reference to the company's ongoing Study 306 we believe that data from this trial could potentially meet the criteria for clinical efficacy and durability of effect data identified in the Complete Response Letter.
As you'll recall, Study 306b is an ongoing 10-week double-blind placebo-controlled trial evaluating Northera in patients with symptomatic neurogenic OH associated with (inaudible). The primary endpoint for this trial is the reduction in the rates of fall per patient per week. However the study is also designed to assess the benefit of Northera in the treatment population using both OHSA Item 1 which measures dizziness, light headedness, feeling faint or feeling like you might blackout as well as the OHQ composite which is a more global assessment of symptomatic and functional benefits.
Since the letter was not specific with regard to the design of a longer confirmatory study, we will need to speak to the agency regarding the suitability of 306b to meet their request. This discussion will of course involve discussion regarding the primary endpoint and if that would be necessary or possible to a co-primary endpoint including both [fall] and either OHSA Item 1 or the OHQ or change in the endpoint altogether.
Until we have these discussions, it is difficult to speculate in great detail as what will be the final path forward or the time forward towards the possible approval. However preliminary estimates suggest that given our enrolment in 306b, the time required to prepare the result with submissions, we could potentially submit a major amendment to our NDA as early as first quarter of next year. Once we have designed our path forward with the agency we will of course look to update you with more vision at the timeline through submissions and potential approval.
Now, in addition to the clinical request made by the agency there were a number of additional requests and recommendations made in the complete response letter. For the most part these are not issues that will prevent approval or time-to-market. As we indicated in the press release, the agency would like to see additional bioequivalence work in order to approve the 300 milligram capsule. Just to clarify, our clinical trials were conducted using combinations of 100 milligrams and 200 milligram capsules.
Our interest in approving a 300 milligram capsule would simply be for ease of administration and we could certainly launch with only 100 and 200 milligram capsules. Of course, given that we will be working to complete clinical requirements for approval, conducting the necessary bioequivalence work to approve the 300 milligram capsule shouldn't be an issue and we anticipate this could be really accomplished prior to an FDA approval of Northera.
Finally, the complete response letter included draft recommendations regarding our labeling. I would like to emphasize that, we did not have an opportunity to engage in meaningful discussions with the agency regarding our label. So while these recommendations are informative they are not final and would not certainly be dependent on the final outcome of future studies and the collected datasets.
As we set forth in the press release, the agency recommendation, narrowing the scope of symptomatic benefits claim to emphasize dizziness, lightheadedness, feeling faint or feeling like you may black out, as the clinical benefits associated with Northera treatment. The only other item of note in the labeling recommendations was that the FDA at this time made a preliminary recommendation to include a black box warning related to supine hypertension. However, the letter indicates such a black box warning could be reconsidered a suitable data, demonstrating lack of severe hypotension, were provided.
As you may recall this topic came up during the advisory committee at a time which we explained that, in keeping up with the standard of care and clinical practice. Patients are advised to maintain a 30 degree head-up tilt in a more supine position. Panelists in the agency expressed interest in testing supine hypertension in patients, when they are in a fully prone position. Given the convincing nature of lack of severe supine hypotension, relative to placebo in our clinical trial, we would expect to see a similar lack of significant, severe, supine hypotension compared to the placebo in a fully prone position. We look forward to get a better understanding from the agency to the scope of the data they would be interested in seeing, in order to remove the potential black box warning from our draft label.
That said, as you are well aware Midodrine has a similar black box warning, though ultimately this is not a significant competitive disadvantage. None of the recommended label changes included discussions around the black box warning, meaningful change or meaningful change apart from pricing or potential market opportunity for Northera. We look forward at the appropriate time to continuing discussions with the agency regarding a potential label for Northera.
Finally, with respect to the complete response later from the agency, I would like to point out that beyond continuing to provide complete safety data as our clinical program progresses, the letter did not identify any outstanding safety concerns related to our NDA submission. We think this is particularly significant in the light of the briefing document issued by the agency before the advisory panel meeting and the emphasis in those documents on safety and are pleased that the data presented during the panel meeting appears to have mitigated these initial concerns related to our submission.
Before I open up the call for questions, I would like to take a minute to share our gratitude for physicians, nurses, study coordinators who conducted our clinical trial and especially the patients, who participated in medical science to help bring this drug to market by participating in our extensive clinical program to-date.
In closing, I would like to emphasize our faith in Northera remains strong as ever. The testimony we have heard from patients regarding the profound effects, they've experienced participating in our clinical trials is among the most moving I've had the privilege to hear.
Though yesterday's response from the agency was indeed a setback, we're committed to doing our best to help those that continue to suffer from symptomatic neurogenic OH, patients who have been waiting for long treatment options to help alleviate their mediated symptoms. We recognize that Northera may meet an unmet significant need for those patients and continue to look forward to bring in this product to these patients.
Now, I would like to turn the call over to questions. Operator?
Question-and-Answer Session
Thank you. (Operator Instructions) Our first question is from Robyn Karnauskas of Deutsche Bank. Your question please?
Robyn Karnauskas - Deutsche Bank
Good morning. So I guess my first question is regarding supine hypertension. Are you collecting, I think if I remember correctly, in the briefing document they highlighted the fact that you did not collect fully supine, blood pressure measurements. So I am just wondering in the 306 study, are you testing fully supine blood pressure and if not, would you have to do an additional trial? Could you do one in a very short period of time to sort of show that this chart does not have higher supine blood pressure?
Dr. Simon Pedder
Well, thanks for the question, Robyn. First of all, no, we're not looking into 306 for patients to be flat. The rationale for that we discussed with investigator. Investigators would never tell a patient to lie flat, who have this disease. I think the important thing here is, regardless of the 30 degrees, this is why there is a placebo component in all trials five to do a comparator and the differences we expect out of 30 degrees between placebo and active would be the same difference that we would expect between placebo and active, if they will look flat at zero degrees. That being the case, I don't think we need to do a trial, a specific trial to do that. I think that we could design something appropriately, to show what the differences may be, that would be informative to the FDA, but of course we really can't finalize anything until we have a discussion with the agency and the rationale, why that we think the difference between placebo and active, that 30 is representative of what would be seen if they lie completely flat.
Robyn Karnauskas - Deutsche Bank
Okay. That's helpful. Then on the FDA discussion, I guess the first question, what is typical timing of having a conversation with the FDA and or how could it help the investors get that color? Then I guess you mentioned that maybe 306 might be able to be sufficient to satisfy the requirement but the full trial is the primary end point and I know mentioned it may be in your core program. Do you think the fact that falls in the end point would be a hurdle for using 306 to support the FDA's questions?
Dr. Simon Pedder
When it comes to timing for the FDA, I think it is normally about 60 days. Bill is in the room, so he can just comment.
Bill Schwieterman
Yeah I mean this variable it is difficult to predict, because those lie between class and between divisions, Simon is right, it is usually within 60 days you get it, sometimes sooner, sometimes later.
Dr. Simon Pedder
And now, your question about 306, we are obviously looking at both right now as plan that to be part of supplemental NDA. But we are also looking at the OHQ, so we'll have all of the individual items of the OHQ in the competitive score. And we're going to have a meeting with the agency to discuss this very point and that will obviously be a main agenda point during the meeting.
Robyn Karnauskas - Deutsche Bank
And then cash, you've mentioned if you were to launch, you can get through probably till early 2013, I think our math suggested you could probably go into second quarter 2013; maybe give us some sense of how you plan to conserve cash to ensure that we can make it through I guess at least the fourth quarter fall data and beyond what is your plan for cash?
Dr. Simon Pedder
I'll hand that over to Nick.
Nick Riehle
Hi Robyn, as we discussed on the last couple of conference calls, the commercial team has made a real effort to constrain spending, I mean just as an example of this despite the positive outcome of the sales reps that we've been recruiting have been, was done so on a contingent basis, especially we've got no liabilities on pulling back those sort of expenses.
Accordingly, we will end March with over $50 million in cash and we are already taking steps necessary to quickly reduce the burn rate. Significantly, as Simon discussed earlier, we have looked at various scenarios for acquiring the data that the FDA is requesting and we are doing with cash on hand, that it is likely to be more than adequate to get out of such data and somewhat beyond that.
Robyn Karnauskas - Deutsche Bank
I guess lastly, with the delayed sort of approval, you know raises questions around IP and of course if you won't get an OHS, you need to get orphan drug designation. But can you just remind us again like what are the options for patent expiration; I think your patent goes out to 2020 and then you might be able to get [high tracks] and then also the site competition for 306 in the US versus EU?
Dr. Simon Pedder
Well, that's one of the attractive feature of droxidopa Northera having off of that, is that when you are dependent on IP, everyday that you don't get approved, you are losing value for your asset. With orphan status you get seven years from approval and so we would not be losing any of our timeline, we will get seven years of protection in the US upon approval. We get 10 years of protection in US and in Europe.
The other thing where we do now have IP around is our control release once-a-day, the droxidopa, but that kind of goes out to 2026. So from a protection viewpoint, we're in really good shape. Of course with the once-a-day, that's a whole different development program that we're getting into in due new course, but our focused opportunity right now is getting the present formulation approved here in the US for NOH.
Robyn Karnauskas - Deutsche Bank
And the site competition of 306, US versus EU that was an issue that's raised with the FDA?
Dr. Simon Pedder
Well, 306 is all done in the US. I would like to point out that the largest benefit in Study 302, to grow the efficacy of 302 were in the Parkinson patients in United States. If we combine 301 and 302 together, it really does show very similar outcome when it comes to geography, when it comes to disease and it's a situation of you get very small numbers when you get into the subgroups. So we combined 301 and 302, it doesn't differ from geography, doesn't differ from the disease.
Thank you. Our next question is from Juan Sanchez of Ladenburg. Your question please.
Juan Sanchez - Ladenburg
If 306 be enrolling patients in the US in majority or not and if you can give us a recap of the safety finding of Study 306a?
Dr. Simon Pedder
Sure. 306 is all being recruited in the US and the safety from 306a was similar to what we previously reported for other trials and that's basically no real difference from placebo.
Juan Sanchez - Ladenburg
And can you remind us, it was some derivative for physical significance, but in Item 1 where was the (inaudible) placebo in 306a?
Dr. Simon Pedder
Yeah, it range from one week, a unit difference of 1.5 to week eight; it was a delta difference of 0.9. So very similar kind of what we reported in 301.
Juan Sanchez - Ladenburg
On OHQ 1, that's 1.5, right?
Dr. Simon Pedder
The OH showed a nice delta early, which we dictated overtime mostly to placebo increases by week eight.
Thank you. Our next question is from Jonathon Eckard of Leerink Swann. Your question please.
Jonathon Eckard - Leerink Swann
So with regards to 306, it is one of the larger trials that you have conducted. Is there any powering around some of the secondary endpoints such as OHSA Item 1? And then also that endpoint, if I am not mistaken has been positive on old trials with 302, which primarily use the different trial design. Can you talk a little bit about the differences in the trial design and how this item might be favorable in this coming trial?
Dr. Simon Pedder
Yeah, I will start off and I'll let Bill and Art jump in if they want to add anything. You know, 306 is powered for a [falls] benefit and when we planned this study, this study was planned as part of the supplemental NDA.
That being said, the number of that powering for a falls benefit came out to 160 patients. 160 patients you will recall is the same number that we ended up recruiting for Study 301 which was powered for an OHQ benefit and there it will be same powering for OHQ as for Item 1, so that seems to be, 160 patients seems to be around the same ballpark as what we would need.
Clearly, we want to have a talk with the agency though and kind of talk about how we should look at 306 to conclude any kind of discussions with regards to the number of patients to be enrolled and finalize that with the agency before we talk to anybody else.
Bill Schwieterman
And the only thing I'll add to that Jon, its Bill that 302 was a withdrawal study and because of the punitive carryover of FDA that might be minimized and in fact will probably explain some of the findings of very sensitive endpoints. 306 as you recall, 301 is an induction design study and in addition to that there are other advantages on 306 which is why Art and I designed it that way to avoid that carryover effect of that open label filtration period as well. Through the patients in 306 does not in the drug and that helps you with the power; obviously we have to discuss with the agency how all of that plays out in terms of overall power and design and we think that those are advantages.
Thank you, our next question is from Scott Henry of Roth Capital.
Scott Henry - Roth Capital
I guess my question is more discussion oriented, but from my perspective it seems there has been somewhat of a pattern of trying to change trial and trying to meet the FDA requirements with something slightly different than they are asking for. At some point do you think it is necessary to start from scratch, to design a trial in line with specifically what they are asking for and delivering it, I mean how do you think about that versus trying to take a different trial in fitting that into the box they are looking for?
Dr. Simon Pedder
Yes well I would approach that to say that you know we are kind of really pioneering the space. The only other experience is obviously with Midodrine and you know there were seven trials with Midodrine. I think the FDA is still waiting hopefully for the next two to show symptomatic benefit. We have demonstrated symptomatic benefit, we have demonstrated symptomatic benefit in the larger studies that's reported in this population, I think that's a huge win for us. You know Dr. Temple said clearly it's a big win and in our previous discussions with the leadership at the FDA they have been very upfront about the fact that this is a hard to see study and that no one has reported symptomatic benefit.
Even when we showed them the data from 302, they highlighted the fact that you know there is clear symptomatic benefit albeit not in the primary as we expect to and you know we learned an incredible lot from these studies, we are going to learn an incredible lot from Study 306. 306 obviously we are putting forward as a second in trial that could lead to approval and in this indication, but I think we are going to learn a tremendous lot about what the benefit is involved, what the benefit is in Parkinson's of these patients so that may be above and beyond NOH.
So this is what clinical trials should be. Clinical trials should be a learning experience. Unfortunately we are not bringing the (inaudible) to market using the HCR-20 as the primary outcome. This is a market where there is no benefit demonstrated in a clinical trial before we came along, it's a learning experience for us. I am sure it's a learning experience for the FDA and the best way forward is for us to get down to the agency and talk about the way forward and once we do that, we will be very upfront and open about what we and the agency have agreed as the best way forward.
Scott Henry - Roth Capital
Okay and obviously you are going to meet with the FDA and find out specifically what they are looking for. In the scenario that 306 does not fit that requirement, could you talk about what the time and the cost of a new trial would be?
Dr. Simon Pedder
You know that's something that we have haven't really explored at all. I mean clearly we have a lot of faith in the Study 306, we think it's a very good design and still outlines the rationale for why it was designed so. We have seen the data from 306a, you know it does indicate efficacies especially with looking at dizziness and the safety again was beyond approach. So you know we obviously are right now planning on completing 306b and obviously having significant discussions with the agency about how that would be suitable to lead to an approval because I think it's no doubt that this drug works in the patient population.
Scott Henry - Roth Capital
Yes it does appear to work. Then I guess asking that question in a couple of different ways and hopefully I have my 300 numbers correct, but trial 301, how long did that trial take to complete and what was the approximate total cost?
Dr. Simon Pedder
It's approximately 2 years, total cost for it you know I'm guessing $20 million and $25 million in the ballpark, we can't give you specifics and that's with the general.
Scott Henry - Roth Capital
Yes that is more than good enough.
Bill Schwieterman
And that too was that it was being done largely concurrently with the 302 study and so some of the costs were somewhat overlapping.
Scott Henry - Roth Capital
And then you know another question for you, if the FDA did, again if they didn't think 306 was sufficient, would you anticipate that you would want to run another trial, I would expect you would because the drug appears to work, but I just wanted to get your thoughts on that?
Dr. Simon Pedder
Well you know I think part of the discussion we will have with the agency would be that you know if 306 did not work to take something that we don't think has happened, but if 306 did not work, what other additional trial would they buy into based on what they have learned and based on what we have learned going through the process and you know I think that we would take our collective education and design additional trial because clearly this is a drug that works. We have a lot of patients who have demanded access to this drug that we have made available in long-term extensions or compassionate release and I think you heard the story from many patients and caregivers that the advisory committee of the benefit, certainly when we show the buckets of responses that are 2,3,4, 5 unit improvements whether or not it's the dizziness or the OHQ as a composite score clearly identifies that a significant number of patients have a very robust benefit to this drug. The FDA would understand that and I think the FDA wants to work with us to make sure that we get that drug to them in a short time as possible.
Thank you. (Operator Instructions). Our next question is from Liana Moussatos of Wedbush Securities.
Liana Moussatos - Wedbush Securities
Just following up a little bit on Robyn's question about the positioning of the patient in 306b versus what was mentioned in the Complete Response Letter, can you go through that again like 30 degree head-tilt versus laying prone and then the other question I have is when will you request the meeting with the FDA?
Dr. Simon Pedder
I will take the last question first and that is immediately we will request a meeting with the FDA. When it comes to the head tilt you know how the standard of care for people who treat these patients is to measure supine hypertension, a (inaudible) table at about 30 degree inline, that's the standard of care. So that's what we did, that allows the comparison between active and placebo in a relatively supine position which all investigators say that's the way that they do it. You know to really make these patients becomes supine and get high blood pressure is questionable, that's why the access in the field report that a better comparison would be would be appropriate at 30 degree tilt.
Our next question is from Jonathan Eckard with Leerink Swann.
Jonathon Eckard - Leerink Swann
I was just going to have as maybe Bill if you could talk about some of the aspects Midodrine profile according to their label and other kind of key differences that you see in your falls profile, not try and tell you to predict the label through that or a [label] with that, that would be differentiating if both drugs had a block box warning initially.
Bill Schwieterman
That's an interesting question John, because they're not natural to midodrine's label but they have a black box for supine hypertension, we intend to cover the key back. I'd like to mention that FDA is offering us the possibility of not having that supine hypertension if we have discussions with them being in the flat position for [drug intake]. That's that's a real advantage. As you know, the midodrine study is quite a bit smaller than what FDA is asking us to do an ARM program and I am not sure why that is, but I think we are going to have discussions with them about what they need to know. Certainly our own way forward would involve according to this communication with FDA, longer-term studies that they want to see out to 8 to 10 weeks. I don't think that might have been keeping currently that they would have that data at all. So there's a couple of differentiating factors right there. The possibility for us going in there with the supine hypertension, which we've always said to take advantage, now we are going to have a much larger and a much longer dataset than the midodrine data have. I think that's an advantage but Keith why don't you chime in here.
Keith Schmidt
Sure. With regard to the black box warning between the two labels, I mean Simon mentioned that the FDA's comments were that that black box warning that they put in the draft right now could come out, if we can demonstrate that there's a lower incidence and we frankly have already done that with our clinical trial today. We showed a much lower incidence of supine hypertension at the 180 millimeters in mercury for sure and at the 200, even more so, because the label, if you look at midodrine's label it talks about patients with supine hypertension in the 22% to 25% dose range. The other thing that's in their black box warning is the admonition to physicians that the product has never shown any symptomatic benefits and so it's a product out there has a real problem in the terms of benefits to risk ratio, why would you risk supine hypertension if the product really doesn't show any benefit to the patient.
So that's the issue, the safety arm with their black box. I am pretty confident that with the data that we can generate that, we will be able convince to the FDA that our product is safe, it doesn't have the nearly the incidence of supine hypotension. And I would add to that, that the FDA also noted in our letter that they were removing the RIMS requirement. So that there is no risk mitigation strategy required because they didn't see the benefit. They didn't see the risk of the product of wanting a RIMS program. So keep that in the back of your mind as well.
The other difference between frankly midodrine and Droxidopa has to do with alpha agonist adverse events and that is the part that drives the frail and elderly patients' berserk. Because it causes the numbness, the tingling in the scalp, the needle prick sensation, it's the kind of thing that really makes it difficult for the patient to comply. The other thing, as you know, alpha agonists have the same products that are used for urinary incontinence. So if you put an elder patient on product like this and what does it do? It makes urination painful. It causes urination to be hesitant, etcetera and if you could imagine if you are an older man, that just isn't what you need. So it's not a happy product for frail and elderly patients to be taking and what physicians do to try to overcome this problem is they under-dose midodrine. They put it at lower doses or they do the dosing less infrequently, trying to get the patient to tolerate it and as we have done our market research, we have heard many times that physicians tell us, they simply can't get the efficacy that they know the product is probably capable of giving, because the patients can't tolerate the dose or can't tolerate the product nature of the adverse events.
Dr. Simon Pedder
And just the kind of follow up for the supine hypotension question you said Jonathan, I would just recall to you that the difference that we saw in our placebo components of the trial was 3% of patients on Droxidopa having supine hypertension over a 180 versus 1.5 on placebo. So the difference was really 1.5% greater than 180.
The midodrine label states at 13% will get supine hypertension but over 200. So there is a real difference that back and forth that we would have with the FDA and the labeling, we would want a more descriptive detail that would fully demonstrate what the difference was seen in our studies compared to what's been seen in midodrine.
Jonathan Eckard - Leerink Swann
That's all very helpful. Just the question was really summed around just where our comparator would be if there was a black box warning and you guys are lined up very well. If I can give another question on a potential label is 306 would be in Parkinson's; with regards to what the FDA then appears to be looking for is durability, maybe it doesn't seem to be an issue. The fact that 306 is only in Parkinson's, in your initial kind of a gut feel, how would that impact the potential patient if that could be included in a label if 306 was allowed to be used. Do you think you will be able….?
Dr. Simon Pedder
I don't think it would and the reason why John is that the MSA and PAF, the other two big patient group were both typically significant when we combined 301, 302 together independently. Parkinson's was closed. In 302, PD patients had the best response; in 301 they had the least response. But combined, they show a similar like benefit on the OHP of about one year improvement across the board. So I don't think there is any concern, I think PAF as in MSA, the data speaks for itself, it very clearly shows us physical significance when you combine 301 and 302.
Jonathan Eckard - Leerink Swann
That's helpful. I guess the last question which, I guess, is probably just looking at this point but, the 306b result at least in the magnitude, the benefit that we saw in 306a was repeated, is a trial in itself as a utility, as a standalone for its own NDA approval?
Dr. Simon Pedder
We would give 306b in conjunctions with the present filing for a future filing for NOH.
Our next question is from [Anatolia Avodarmal of Carnie]. You question please?
Unidentified Analyst
Simon and Bill I wanted to ask if you guys can comment on the timeline of separation in respect to item one in OHQ that we saw in the eight week study, 306A and is there any implication if any, for thinking about 306 B giving the same end points. I think the question is, it does seem like we see some compression of a benefit over time that would be starting at week four. Perhaps less so for item 1 and OHQ? And if we did see, I guess the specific question is, if we did see that kind of benefit compression what would your revised power calculation before 306 B achieving significance in those end points.
Dr. Simon Pedder
Well, I will start off and let Bill jump in. My only comment is, please remember there is only 51 patients in 306A, 27 are on placebo and 24. It was a smaller data set. That being said, the range for the benefit on item one went from a 1.5 unit at week one to a 0.9 unit difference at week eight. So although it did compress a little bit, they would still be what we see at 0.9 is what was reported in 301 and I will point back to that at obviously a range of benefits. And as we demonstrated at the Advisory Committee that a lot of these patients that were having benefit were the patients who were having robust benefit of two units, three units, four units, five units, six units improvement on dizziness. So we feel relatively comfortable that 306b will show the same outcome. Bill?
Bill Schwieterman
Yeah, I don't have much to add to that. I think you know what we saw in 306b was more numbers of patients to begin with, so it's really difficult to make any firm conclusions regarding the temporal effects and so forth. But you are right it went from 1.5 to nine and that was largely driven by placebo effects in some of the patients coming out.
I think overall it is also fairly consistent over the long-term and we remain pretty confident that the 306b data especially when you look at the falls data in that study where you see a 60% reduction in all and really a small number of patients, but we also think that that's an objective out to measure and that's going to be helpful in allowing FDA for the long-term.
Thank you. Our next question is a follow-up from Scott Henry of Roth Capital.
Scott Henry - Roth Capital
Just a couple of follow-ups. I guess first with regard to meeting with the FDA, do you have any sense of the timeline for that; is that something that could occur in the second quarter or do you have any sense on the calendar there?
Dr. Simon Pedder
Yeah, we will be requesting meeting right away and then it would be within 60 days and we'll remind them that this is an orphan status drug and that it's supposed to be more open transparent dialogue with orphan diseases and that we would appreciate if they could meet with us as soon as possible.
Scott Henry - Roth Capital
And then the bigger picture question is and obviously you've got the benefit of greater dialogue with the FDA than we do; when you think about 306 confirming 301, they have different endpoints. So to me, that's obviously not a simple confirmation. Do you think that falls data can confirm the composite endpoint or do you think that the composite endpoint would have to confirm the composite endpoint?
Dr. Simon Pedder
Well, at the Advisory Panel what Dr. Temple mentioned is that you can look at all the endpoints if your primary meets fiscal significance, then you can decide what's really important based on looking at all the data. And clearly from the analysis that the same group did at the FDA, they highlighted instruments that, dizziness was clearly the most cardinal symptom of NOH in their research and it was pointed out by our own research and they seemed to have highlighted the fact that improvement on dizziness is what really key for these patients.
And so although we look at the OHQ as a group and works basically significant with them, there was the fact about directing what they felt was more clinically meaningful and ambiguous with these patients and that is improvement on dizziness which obviously had a FDA point towards 301.
And because of that I think that again as an education and learning experience going forward we learned from these trial, that clearly maybe Item 1 is the most robust and the more appropriate and that's good for us because, in the biggest study we ever did, we had a 1.3 unit improvement and patients had typically significant improvements to the patients who had a two, three, four, five, six unit improvements compared to placebo.
So I think what they are learning and what we're learning is that dizziness maybe the key thing to look at and we think that's probably a big win for us. Bill, Art can you sum that?
Bill Schwieterman
The only thing I'll add to that, FDA actually has a long history of using complementary trials upon in different endpoints to collaborate and show consistency as a fact. So I don't think its vast replication. It has never really been amended at the FDA what they wanted an efficacy data that are convincing, showing them data.
And I think one of the advantages of our program and our drug actually is that it shows benefits across a range of our company; it is a hard questionnaire which showed significant it could be, one that they pointed out at the advisory committee, it's also important business. We also showed a real significance; we have early data showing that shows benefit in 306, efficacy data on 301 (inaudible).
Thank you. Our final question is from [Michael Hagen of Winston Patrick Securities]. Your question please.
Unidentified Analyst
I am wondering if and apologies if I am repeating constant here, but I am wondering if the black box would be due to an inclusion of 300 milligram dose and if so, how important that 300 milligram dose is to you?
Dr. Simon Pedder
No, I don't think we saw any dose response when it came to supine hypertension. So it's not really a dose issue. Even with small amount was droxidopa, if these patients have complete lack of (inaudible) they can have a blood pressure response in the low dosages. So it's really independent of doses and that's patient-by-patient and that's why we really key on that slow, but steady titration to benefit, so that they can bounce off the benefit of the drug versus potential issue such as attention.
Unidentified Analyst
And a follow-up class expansion, you've got the question earlier and do you think that this would be Class I or Class II review considering the 3 milligram dosing and can you repeat that would you think the 3 milligram is worth go to the Class II and including the data would you be more apt to leave that on the side and hope for a Class I review considering the orphan status?
Bill Schwieterman
I think I don't want to speculate too much until to speak to FDA and so I think we need to get some ideas about what they really want specifically. So we think about the actual. But I looked at that and I think the 3 milligram dose issue is not really the one that FDA is going to focus on, and certainly not the one that we go into a response but we really have to do more with the 306b data.
And the Class II responses are generally are reserved for those; I was reviewing it last night again, you know with the involvement sort of we're in discussion and so forth. And so if the FDA once go out and (inaudible) 306b then it would be a Class II. It's conceivable and we might view it differently that as Class I but I don't really want to get into that.
Dr. Simon Pedder
And with that, we appreciate the questions and I think that all we can do is once we've met and talked to the FDA we are obviously going to update you people accordingly.
Thank you. That concludes our question and answer session for today. I would now like to turn the conference back over to Dr. Simon Pedder for any closing remarks.
Dr. Simon Pedder
I just like to summarize by thanking you all for your interest and your support. Obviously, we've got a very important meeting with the FDA and we look forward to updating you on our plans and moving forward to this very important drug and treating this unmet medical need so (inaudible). Thank you.
Ladies and gentlemen, thank you for your participation. That concludes the presentation. You may disconnect and have a wonderful day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!


text:
Hotels in Fiuggi, Italy
Search & Compare Fiuggi Hotels
Get Secret Prices on select hotels
These prices aren't available to everyone.
Trending now in Fiuggi
- Most bookedAmbasciatori Hotel
493 people looked at this hotel in the last hour
Most recent review
"if you stay at this hotel , it is all about the location. Stayed here because I was doing business in the area. Forget about about the 70's decor , the hotel is in a great location with beach access from the hotel thru a tunnel ."
A Traveller, Sep 2016, IE
440 people looked at this hotel in the last hour
253 people looked at this hotel in the last hour
10 people looked at this hotel in the last hour
Most recent review
"ALL the staff were so accommodating as my luggage did not arrive with me when my flight arrived in Rome and was not going to be delivered to Fiuggi until late the next day. They provided me with a toothbrush, toothpaste a bath robe, slippers and extra blankets and a complimentary beverage. And wh..."
A Traveller, Dec 2015, CA
9 people looked at this hotel in the last hour
9 people looked at this hotel in the last hour
8 people looked at this hotel in the last hour
Most recent review
"The hotel is a two star. However it's clean, comfortable and in great location. It's doesn't have a parking (hence a two star) but parking in Fiuggi is never a problem. Management is family style but impeccable. Breakfast is basic and acceptable."
A Traveller, Jul 2015, GB
7 people looked at this hotel in the last hour
5 people looked at this hotel in the last hour
5 people looked at this hotel in the last hour
Best hotels in Fiuggi
If you are looking for Fiuggi hotels in a particular area, you can use the search feature at the top of the page to search by neighborhood, landmark, address or zip code, or you can search by using the built-in map feature. You can also browse hotels in Fiuggi by type, amenities, and star-rating so that you can find the best hotel. Currently, top rated hotels in Fiuggi are:
- Villa Sardegna
- Hotel Bonifacio
- King Hotel
- Grand Hotel Palazzo Della Fonte
- Ambasciatori Hotel
The location of your Fiuggi hotel is important. If you are traveling to Fiuggi, &StateorCountry for business, you may want to consider getting a hotel close to the airport or near your meeting venue. By doing so, you can really cut down on transportation costs and time. You may also want to book a hotel that offers free wifi just in case you need to get some work done.
If you are traveling for vacation, figure out which attractions or landmarks you want to see and book a hotel that is within close proximity. Although hotels near attractions might cost a little more, you may find that spending those extra few dollars is worth the convenience. You can even find hotels that align with your interests. For example, if you are looking for a relaxing vacation, a spa hotel may be the perfect choice for you.
You'll also want to determine which type of accommodations will suit your needs before booking a hotel in Fiuggi. If you're traveling with the kiddos, a family friendly hotel will offer larger rooms and more sleeping arrangements. For those traveling for an extended period of time, booking a hotel suite with a kitchenette is a smart move and will feel a little more like home. If you are budget conscience and just need a place to rest your head, a hostel or motel may be all you need.
If you are looking to score the best discounts and deals, use the filter to sort by price from low to high. You can book a hotel in Fiuggi for as low as $34 per night. If you are looking to cut down on expenses, look for hotels that include free breakfast and parking. Some hotels even offer free shuttle service to and from nearby places. You can also sort by star rating, proximity, and guest rating.
Before you book, check out user reviews. Hotels.com has 245 reviews in Fiuggi. We show reviews from Expedia and TripAdvisor so you know that you are reading genuine, reliable reviews. Be sure to download the Hotels.com app so you can book your reservations on the go, view amenities, and save the hotels you want to view and compare later.


text:
Book a Service with Leading Sydney Property Makeover Expert Belinda Grundy
Whether you are looking for an on-site appraisal to steer you in the right direction, a budget driven Do-it-Yourself solution on, the luxury of Done-For-You magic you'll find the perfect solution in one of our packages below.
To help you decide which package is right for you, book Belinda for a free 15-minute phone consultation or for a free meeting at our Mona Vale office – and let us help you get your house on the market.
Our Services & Pricing
Let BG Property Styling take the stress off your shoulders and show you how to get a quicker sale for more money so you can move onto your next property sooner rather than later!
You must hit the market only ONCE – do it right! Avoid the fatal mistake of a relaunch. It will cost you more time, more marketing expense and almost certainly a lower sale price.
Put yourself in the driver's seat and just leave your name and email to download our FREE hottest tips from our "7 Secrets to Property Selling Power".


text:
Just saw this post and hadn't thought about it all day. It's about to go down tonight man.
90 minute finale. I'm beyond hyped.
No. That would completely ruin the show and make it a laughing stock. There's no dumb stuff like that in the movie.
It's about to get heated though.
Now, THIS is how you do a finale. Bravo.
I was glad that didn't do the cliche one of the main characters dies that's popular in modern television now.
I think thats who this guy is. This is a pic from the website but I never saw this scene in the show.
A satisfying finale! Maybe the pacing was just a *tad* slow, but it wasn't a problem for me. Been a great season.
That leg scene tho.
Though I must admit I did want to see Lester run into William H. Macy or something... lol.
Anyway, this was pretty cool...
Team McLAREN HONDA
Fittipaldi, Hunt, Lauda, Prost, Senna, Hakkinen, Hamilton
Seattle Mariners // MUFC
IG: SinnerP
PSN: SinnerP


text:
search all 95,561 blends
by name:
by creator:
by tag:
by fandom:
home > signature blend >
The Grim
created by: Bertolt Brecht
If you see a large black dog about while drinking this tea, don't be startled: he might want to try some of his tea. This tea is dark, rich, dangerous, and will definitely keep you up at night - just like the Grim!
1 reviews
1 recent reviews
click & drag the tin to rotate
blended with lapsang souchong, pu erh dante, black tea, cinnamon bark, ginger root, cocoa nibs, natural chocolate flavor, natural cinnamon flavor
teas: pu erh dante, chocolate chai, lapsang souchong
accented with cocoa nibs
steep at 212° for 3 mins
This tea contains a high level of caffeine
20 additional blends by Bertolt Brecht
Vastra and Jenny
by Bertolt Brecht
chocolate chip, honeybush orange, rooibos vanilla chai


text:
If option three sounds scary and dear you can still exfoliate your complexion around the house. Moisturize, add to your water intake and add exercise to get a routine may possibly all aide in reducing each side the marks. A lot of even go tanning to tighten and balance out their complexion. Be wary of otc supplements creams that promise mark removal. Tastes those creams definitely education Vitamin e d-alpha oil besides other scar treatment medication but is occasionally not efficient.
Stretch marks are seen new home buyers belly. The unlucky ones get these even through hips, breasts, thighs and buttocks. The problem with it's cannot wear your sleek bikini suits round the beach, as compared to the skin scarring surely depressing sight. Try not to be disheartened. You are able surely discard these miserable striae.
In regarding which are non-prescription items, acquire some prescription available options a web based business diminish stretch-marks. A dr may suggest a medication like Retin-A cream. This cream was originally touted with the intention to make people look young, but it surely is successful at making the redness from striae vanish, and will assist in preventing scaring. The only catch with this particular particular item is that he needs to double when stretch marks incredibly young (one year old) although the line is still red or pink.


text:
Lost in Transit: Product Replacement Bias and Pricing to Market
- (pp. 3277-3316)
AbstractIn the microdata underlying US trade price indexes, 40 percent of products are replaced before a single price change is observed and 70 percent are replaced after two price changes or fewer. A price index that focuses on price changes for identical items may, therefore, miss an important component of price adjustment occurring at the time of product replacements. We provide a model of this "product replacement bias" and quantify its importance using US data. Accounting for product replacement bias, long-run exchange rate "pass-through" is substantially higher than conventional estimates suggest, and the terms of trade are substantially more volatile. (JEL F14, F31)
Citation2012. "Lost in Transit: Product Replacement Bias and Pricing to Market." American Economic Review, 102(7): 3277-3316. DOI: 10.1257/aer.102.7.3277
Additional Materials
JEL Classification
- F14 Empirical Studies of Trade
- F31 Foreign Exchange


text:
Once you have been prescribed a statin, it is vital that you continue to take your medication as directed by your doctor. You will need to continue taking your statin medication for the rest of your life, even if you feel well, to reduce your risk of developing cardiovascular disease (CVD). If you already have CVD, taking your statin medication can reduce the risk of developing further problems.
If you forget to take your statin tablet, don't worry; just take the next tablet when it is due. Do not try to make up the missed dose by taking double the dose.
Stopping statin medication may put you at an increased risk of developing CVD. If, for any reason, you are unable to continue taking your statin medication, you should talk to your doctor as soon as possible. Statins are prescribed to prevent serious complications such as heart attack or stroke, so it is important that you discuss your options with your doctor. Statins are generally well tolerated, and have been used and studied in large clinical tests (trials) over long periods of time.
To talk online to others with high cholesterol, you can join HEART UK's patient forum, Health Unlocked: http://heartuk.org.uk/healthunlocked